RT Journal Article SR Electronic T1 Cardiac amyloid imaging with 18F-florbetaben positron emission tomography: a pilot study JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP jnumed.115.169870 DO 10.2967/jnumed.115.169870 A1 W. Phillip Law A1 William Y.S. Wang A1 Peter T. Moore A1 Peter N. Mollee A1 Arnold C.T. Ng YR 2016 UL http://jnm.snmjournals.org/content/early/2016/06/10/jnumed.115.169870.abstract AB Aim: Determine the feasibility of 18F-florbetaben positron emission tomography (PET) in diagnosing cardiac amyloidosis. Methods: 18F-florbetaben PET was performed in 14 subjects: 5 light chain (AL) amyloid, 5 transthyretin (ATTR) amyloid, and 4 control subjects with hypertensive heart disease. Qualitative and quantitative assessments of 18F-florbetaben activity were performed using mean standardized uptake value (SUV) of the left ventricular (LV) myocardium and blood pool, and calculation of target-to-background SUV ratio. Percentage myocardial 18F-forbetaben retention was also calculated as the percentage mean myocardial SUV change between 0–5mins and 15–20mins after radiotracer injection. Global LV longitudinal and right ventricular (RV) free wall longitudinal strain were calculated using 2D speckle tracking echocardiography. Results: Target-to-background SUV ratio and percentage myocardial 18F-forbetaben retention were higher in amyloid patients compared to hypertensive control subjects. A cut-off value of 40% was able to differentiate between cardiac amyloid patients and hypertensive control subjects. Percentage myocardial 18F-forbetaben retention was an independent determinant of both global LV longitudinal and RV free wall longitudinal strain via an inverse curve relationship. Conclusion: 18F-florbetaben PET imaging can accurately identify and differentiate between cardiac amyloidosis and hypertensive heart disease. Percentage myocardial 18F-florbetaben retention was an independent determinant of myocardial dysfunction in cardiac amyloidosis.